|Grabbed mine at the 5p offer.|
|Guess who was attempting to pump this in January:-
and it came to pass that in February there was a massive fund raising. What a surprise.
It's truly a disgrace.|
|There's also a new interview CEO Jamal Rushdy, talking about the fund raising and future prospects:
Jamal Rushdy Interview|
|There a new video interview with the Hardman analyst on Proactive, worth a listen:
The closing comments on valuation are particularly interesting:
Collagen currently valued with an enterprise value to sales multiple of 1.1X sales. A multiple of 3X - 10X sales multiple would not be unrealistic based on peer group comparisons|
|Think the forecasts have been scaled back to very conservative and easily over achieved|
|yeah but its share dilution v's opportunities pipeline. Knew there would be a placing, as cash was teetering. But the money of that qty shows amount of opportunities out there, may end up with lots more in house products than the 3 already in the current short term pipeline.|
|Forgot to say, I was fortunate enough to procure a few (EIS) shares in the placing. My maiden purchase|
|Investors subscribing for the EIS qualifying shares in the placing seem to have been scaled back by around 10%, so the placing was presumably slightly oversubscribed.|
|when the finished devices are complete then this company will be worth a whole lot more. I am surprised a larger company doesnt swallow them up tbh.|
|The slide set from the recent Collagen Solutions presentation at the Shares Mag Growth and Innovation forum (Jan 31st) are now available here:
|I agree, but on a positive slant, these are elements not directly relevant to the bottom line, but more to do with increased 'prestige' a share price judges sales figures, the wider perspective and trajectory is judged by the peripheral, the companies standing... But in a tick up sense.. pants announcements...|
|I must say the quality of the recent announcements is somewhat poor. Attendance at a confrence, award of a studentship, scientific advisory board????- there are only three things that are important- sales, sales and sales not announcements about house keeping. Next thing we know there will be an annoucemnet about the office cleaning contract. If this is the best they can offer us I am not holding out a lot of hope for an uptick in share price anytime soon|
|i bought some at sub 6p to add though.. but I have all these now which is not how it should be done. By Mid 2017 period we should have CE mark news and the 6 years retrospective product assessment analysed, an improved product and all in house and actually ready to go now.. In the mean time get further agreement for supply/partnership in China we will move ALOT.
And also two other inhouse products in the near term pipeline, any of these comes out as news that they are ready to roll out then we move ALOT.
Right news is on the horizon, just have to weather short term bouncing about.. market makers need to make a market.|
|yeah we would all be rich if we knew that, me likewise but I'm interested in the longer story. We could move up from here substantially on a variety of pipeline news... so you take your chances. I dont like going in wrong direction either... for what its worth...|
|When will this move. l was going to sell but l bought at 7p but wont sell at a loss.|
|any ideas on newsflow.. some large sells last couple of days maybe L&G lowering stance again?
Is there anywhere one can find out the progress of a CE mark? or is it not something open to public view?|
|Promotional post - The Growth and Innovation Forum will show you how to take advantage of new investment opportunities in technology stocks and funds. Come and see Jamal Rushdy, CEO - Collagen Solutions and 20 other companies present at the Growth and Innovation Forum on 31st January 2017 at Business Design Centre London. Find the next stock market ‘winner’. Satellite Solutions Worldwide +79%, CyanConnode +43%, Instem + 44%, Summit Therapeutics +32% and XLMedia +46% all attended last year. Click to register to attend for free Https://goo.gl/J9pCpW
The other companies also presenting Jaywing, RedstoneConnect, Blancco Technology Group, CloudCall, Frontier IP Group, CyanConnode, Bango, LoopUp, CityFibre, TP Group, AJ Bell, ANGLE, Legal & General UK Alpha Trust, Defenx, Instem, WANdisco, Collagen Solutions, Avacta, One pm Finance, Cenkos Securities and Mirada. Https://goo.gl/J9pCpW|
|RNS Number : 0795U
Collagen Solutions PLC
13 January 2017
Collagen Solutions Plc
(the "Company" or the "Group")
Awarded third Medical Research Scotland Ph.D. Studentship
Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices, research and in-vitro diagnostics, announces that it has been awarded a third Medical Research Scotland Ph.D. studentship, this time in partnership with Professor Elizabeth Tanner, of the School of Engineering, at the University of Glasgow.
The project, titled "Collagen Calcium Phosphate Composite Devices for Bone Augmentation", will investigate the application of collagen fibrils to provide a scaffold for "critical size defects" in bone, which do not heal spontaneously. To obtain healing, some form of scaffold or conduit for the bone repair process is essential and this project will aim to develop novel collagen-containing biomaterials to aid the healing process for these larger bone defects. The project is a four-year Ph.D. project expected to start in the next academic year.
Commenting on the award, Jamal Rushdy, CEO of Collagen Solutions said: "Our current pipeline includes a novel bone graft substitute product, addressing a segment of the $1.7 billion end-user bone graft market opportunity. This new research programme, funded in collaboration with Medical Research Scotland and Professor Tanner's group within the world-class research facilities at the University of Glasgow, will ensure we continue to innovate in this field. In the future we hope to develop next-generation bone graft substitute technologies, addressing more difficult to heal bone defects, thus ensuring continued scientific leadership in this significant segment of the orthobiologics market."
About Professor Elizabeth Tanner, OBE:
Currently Professor of Biomedical Materials at the University of Glasgow, Professor Tanner received an OBE for services to Biomedical Engineering in 2016 and an honorary doctorate within the Faculty of Medicine, Lund University where she is a visiting Professor.
Her research interests are in the development and use of bioactive materials for bone augmentation and replacement, developing composites of polymers filled with bioactive ceramics based on the mineral phase of bone. One such material developed by her team is HAPEX™, used in over half a million patients since 1988. She has published over 150 papers and book chapters and in 2020 she will be President of the 11th World Biomaterials Congress taking place in Glasgow.
About Collagen Solutions:
Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval. For additional information, please visit www.collagensolutions.com.|
|18BT yes he does... I added yesterday... average down a tad.
And no worries. Steady news flow, and two more customers we know about that they did not announce formerly as an RNS.
We get announcements on timescale for own products, or first contract in China and we will be moving... Just a case of waiting, revenue wise we need to see continued growth, as only blip that I can see is potential slight dilution, if and when cashflow doesn't support the on going short term cash requirements to fund all the avenues and regions of trade... all depends on full year results that one, if we over achieve sales wise it will be slower on no cash burn.|